Experimental evidence has demonstrated that metformin, a common antidiabetic drug in the treatment of DM2, can inhibit the growth of pancreatic cancer cells via a mechanism related to its effect on disrupting crosstalk between insulin/ insulin-like growth factor 1 (IGF1) and G protein-coupled receptor (GPCR) signaling pathways, a system implicated in autocrine-paracrine stimulation of a variety of malignancies, including pancreatic cancer [35]. This evidence concerns the gene INS and pancreatic neoplasm.